Home » BrainStorm Announces Clinical Data Supporting Safety, Efficacy of NurOwn
BrainStorm Announces Clinical Data Supporting Safety, Efficacy of NurOwn
BrainStorm Cell Therapeutics announced that the data from the initial patients in its ALS Phase I/II human clinical trial treated with its NurOwn technology did not present any significant side effects and that the NurOwn treatment has so far proven to be safe.
The Street
The Street
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May